Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBI: Adalimumab, Anakinra, and Tocilizumab in Refractory Non-infectious Uveitis
NCT02929251Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2017
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anakinra and tocilizumab in noninfectious uveitis (NIU), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2017; status: completed.
02
Drugs
anakinratocilizumab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT02929251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929251.